Brokerages forecast that Catalent Inc (NYSE:CTLT) will post earnings per share of $0.64 for the current quarter, according to Zacks. Six analysts have issued estimates for Catalent’s earnings. The highest EPS estimate is $0.66 and the lowest is $0.61. Catalent posted earnings per share of $0.67 during the same quarter last year, which indicates a negative year over year growth rate of 4.5%. The company is expected to report its next earnings report before the market opens on Tuesday, August 27th.

According to Zacks, analysts expect that Catalent will report full year earnings of $1.86 per share for the current financial year, with EPS estimates ranging from $1.82 to $1.87. For the next fiscal year, analysts expect that the firm will post earnings of $1.98 per share, with EPS estimates ranging from $1.93 to $2.09. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research firms that follow Catalent.

A number of research analysts recently issued reports on the stock. UBS Group lifted their price target on shares of Catalent to $64.00 and gave the company a “buy” rating in a research report on Tuesday, July 23rd. Jefferies Financial Group upgraded shares of Catalent from a “hold” rating to a “buy” rating and raised their price objective for the company from $50.00 to $62.00 in a research note on Friday, June 21st. Finally, Zacks Investment Research lowered shares of Catalent from a “hold” rating to a “sell” rating in a research note on Monday. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $55.14.

Shares of CTLT stock traded up $0.13 on Thursday, hitting $55.29. 16,572 shares of the company’s stock traded hands, compared to its average volume of 654,759. The company has a quick ratio of 1.71, a current ratio of 2.18 and a debt-to-equity ratio of 1.31. Catalent has a one year low of $29.23 and a one year high of $58.38. The firm’s fifty day moving average is $55.22. The stock has a market cap of $8.06 billion, a PE ratio of 34.76, a price-to-earnings-growth ratio of 2.72 and a beta of 1.64.

In other news, SVP Steven L. Fasman sold 4,053 shares of Catalent stock in a transaction that occurred on Thursday, July 11th. The shares were sold at an average price of $54.04, for a total value of $219,024.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Peter L. Buzy purchased 44,500 shares of Catalent stock in a transaction dated Wednesday, May 29th. The stock was bought at an average price of $45.13 per share, with a total value of $2,008,285.00. Following the completion of the purchase, the insider now directly owns 44,500 shares of the company’s stock, valued at $2,008,285. The disclosure for this purchase can be found here. 1.40% of the stock is currently owned by company insiders.

Several hedge funds have recently made changes to their positions in CTLT. Evolution Wealth Advisors LLC acquired a new position in Catalent in the 2nd quarter worth approximately $32,000. Advisory Services Network LLC lifted its stake in Catalent by 115.5% in the 2nd quarter. Advisory Services Network LLC now owns 737 shares of the company’s stock worth $39,000 after purchasing an additional 395 shares in the last quarter. Financial Gravity Wealth Inc. bought a new position in shares of Catalent in the 1st quarter worth $47,000. Bremer Bank National Association bought a new position in shares of Catalent in the 1st quarter worth $49,000. Finally, Zions Bancorporation N.A. bought a new position in shares of Catalent in the 1st quarter worth $61,000. Hedge funds and other institutional investors own 96.85% of the company’s stock.

Catalent Company Profile

Catalent, Inc provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

Featured Article: Understanding debt-to-equity ratio in fundamental analysis

Get a free copy of the Zacks research report on Catalent (CTLT)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with's FREE daily email newsletter.